Faculty

Cathy Critchlow

Affiliate Professor, Epidemiology


ccritchl@amgen.com

Education

PhD Epidemiology, University of Washington, 1993

Contact


ccritchl@amgen.com

View Website »

Bio

Since 2004, Dr. Critchlow has focused on epidemiologic methods relevant to pharmacoepidemiology, conducting studies and developing observational research strategies in support of drug development and assessment of post-market drug effectiveness and safety.  She currently heads the Center for Observational Research at Amgen, Inc. 

Research Interests

Dr. Critchlow’s research focuses on pharmacoepidemiology methods to assess the evolving benefit:risk profiles of medications used in clinical practice populations, including application of methods to control for confounding-by-indication in studies of treatment effects, post-marketing drug surveillance studies and longitudinal data analysis using large databases.

Recent Publications (PubMed)

Characteristics and outcomes of hospitalised adults with COVID-19 in a Global Health Research Network: a cohort study.
(2021 Aug 6)
BMJ Open 11(8): e051588
Zhu J, Wei Z, Suryavanshi M, Chen X, Xia Q, Jiang J, Ayodele O, Bradbury BD, Brooks C, Brown CA, Cheng A, Critchlow CW, Devercelli G, Gandhi V, Gondek K, Londhe AA, Ma J, Jonsson-Funk M, Keenan HA, Manne S, Ren K, Sanders L, Yu P, Zhang J, Zhou L, Bao Y

Real-world evidence to support regulatory decision making: New or expanded medical product indications.
(2021 Jun)
Pharmacoepidemiol Drug Saf 30(6): 685-693
Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA

Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
(2020 Oct)
Pharmacoepidemiol Drug Saf 29(10): 1228-1235
Burcu M, Dreyer NA, Franklin JM, Blum MD, Critchlow CW, Perfetto EM, Zhou W

Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database.
(2018 Apr 10)
BMC Health Serv Res 18(1): 263
Wang FT, Xue F, Ding Y, Ng E, Critchlow CW, Dore DD

Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
(2017 Nov)
Pharmacoepidemiol Drug Saf 26(11): 1357-1366
Gawade PL, Berlin JA, Henry DH, Tomita D, Brooks BD, Franklin J, Bradbury BD, Critchlow CW

Show complete publication list

In the News

No news articles at this time.